Hospital
Good Samaritan Hospital of Suffern
Good Samaritan Hospital of Suffern was paid $18.96M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoGOOD SAMARITAN HOSPITAL OF SUFFERN
SUFFERN, NY 10901
SUFFERN, NY 10901
33aNPI1346213469assigned 02/09/2006
33bProvider typeRehabilitation Hospital Unit
28Total paid$18.96M
24GClaims419,471
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Hospital Unit providers in New York
Rank by total paid#2 of 7
Median peer was paid$58K
This provider vs. median325×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,916 | $247K | |
| 2019 | 25,319 | $1.25M | |
| 2020 | 58,489 | $2.62M | |
| 2021 | 77,981 | $3.63M | |
| 2022 | 87,418 | $3.93M | |
| 2023 | 89,240 | $3.91M | |
| 2024incomplete | 77,108 | $3.39M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 14,635 | 13,985 | $2.63M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 14,148 | 13,611 | $2.62M |
| 36415 | Collection of venous blood by venipuncture | 12% | 115,558 | 28,714 | $2.20M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.2% | 6,435 | 6,187 | $1.17M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.7% | 4,992 | 4,861 | $892K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 4.5% | 4,326 | 2,577 | $856K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.9% | 3,245 | 2,381 | $743K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.9% | 2,778 | 2,568 | $732K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 2,325 | 2,301 | $677K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 2,325 | 2,274 | $647K |
| 80053 | Comprehensive metabolic panel | 2.3% | 20,937 | 19,198 | $439K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.1% | 542 | 537 | $402K |
196 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 1,652 | $377K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 1,260 | $339K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 4,404 | $331K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.6% | 1,894 | $297K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,673 | $186K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 991 | $170K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 8,555 | $167K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 166 | $154K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 844 | $142K |
| T1030 | Nursing care, in the home, by registered nurse, per diem | <1% | 901 | $140K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 225 | $126K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,136 | $115K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,681 | $114K |
| 86850 | <1% | 3,627 | $113K | |
| 86900 | <1% | 3,675 | $108K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 631 | $107K |
| 86901 | <1% | 3,676 | $103K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,146 | $96K |
| 59820 | <1% | 81 | $83K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,591 | $78K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 638 | $78K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,488 | $72K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,918 | $68K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,149 | $67K |
| 88342 | <1% | 973 | $64K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 234 | $63K |
| 59025 | Fetal non-stress test | <1% | 255 | $62K |
| G0378 | Hospital observation service, per hour | <1% | 379 | $61K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 159 | $53K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 939 | $52K |
| 97161 | <1% | 423 | $45K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 333 | $41K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,844 | $38K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 426 | $37K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,914 | $32K |
| 83880 | <1% | 1,049 | $31K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 741 | $31K |
| 93971 | <1% | 411 | $31K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 97 | $29K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 15 | $28K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 712 | $27K |
| 76801 | <1% | 190 | $27K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,673 | $27K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,216 | $26K |
| 81025 | <1% | 7,196 | $24K | |
| 88304 | <1% | 862 | $24K | |
| 76641 | <1% | 718 | $23K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 26 | $22K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,042 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,618 | $21K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,529 | $17K |
| 80061 | Lipid panel | <1% | 1,846 | $17K |
| 93970 | <1% | 41 | $16K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,025 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 485 | $15K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 198 | $13K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 53 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,647 | $13K |
| 59812 | <1% | 12 | $11K | |
| 0012A | <1% | 409 | $11K | |
| 76770 | <1% | 57 | $11K | |
| 76820 | <1% | 177 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,386 | $10K |
| 80076 | <1% | 1,028 | $9K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 386 | $8K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 90 | $7K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $7K |
| 82607 | <1% | 621 | $7K | |
| 85027 | <1% | 2,692 | $7K | |
| 95806 | <1% | 234 | $7K | |
| 92588 | <1% | 94 | $6K | |
| 0011A | <1% | 340 | $6K | |
| 76818 | <1% | 63 | $6K | |
| 85730 | <1% | 6,478 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 876 | $6K |
| 93296 | <1% | 117 | $6K | |
| 96415 | <1% | 114 | $5K | |
| 84439 | <1% | 741 | $5K | |
| 12001 | <1% | 12 | $5K | |
| 85610 | <1% | 7,018 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 706 | $4K |
| 0001A | <1% | 108 | $4K | |
| 99051 | <1% | 221 | $3K | |
| 81001 | <1% | 5,203 | $3K | |
| 0002A | <1% | 89 | $3K | |
| 83735 | <1% | 4,187 | $3K | |
| 82784 | <1% | 232 | $3K | |
| 81003 | <1% | 6,653 | $3K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 25 | $3K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 49 | $3K |
| 87040 | <1% | 1,542 | $3K | |
| 97010 | <1% | 138 | $2K | |
| 83690 | <1% | 4,806 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,363 | $2K |
| 84484 | <1% | 5,203 | $2K | |
| 86920 | <1% | 31 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 608 | $2K |
| 85379 | <1% | 1,305 | $2K | |
| 0031A | <1% | 40 | $2K | |
| 82977 | <1% | 316 | $2K | |
| 82550 | <1% | 462 | $2K | |
| 97162 | <1% | 13 | $2K | |
| 0064A | <1% | 37 | $1K | |
| 83605 | <1% | 1,639 | $1K | |
| 84702 | <1% | 1,954 | $1K | |
| 73630 | <1% | 181 | $1K | |
| 83540 | <1% | 299 | $1K | |
| OP250 | <1% | 196 | $1K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 27 | $1K |
| 86364 | <1% | 97 | $1K | |
| 87186 | <1% | 649 | $1K | |
| 97164 | <1% | 13 | $1K | |
| 86618 | <1% | 59 | $1K | |
| 82728 | <1% | 102 | $1K | |
| 96376 | <1% | 118 | $973.41 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $960.60 |
| 87070 | <1% | 1,156 | $946.28 | |
| 86140 | <1% | 246 | $936.04 | |
| 84153 | <1% | 56 | $900.19 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 25 | $869.43 |
| 85652 | <1% | 496 | $725.01 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 98 | $720.00 |
| 82962 | <1% | 2,223 | $718.05 | |
| 87088 | <1% | 370 | $653.68 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 21 | $619.20 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 83 | $619.20 |
| 82077 | <1% | 1,253 | $607.20 | |
| 90715 | <1% | 25 | $535.52 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 25 | $511.09 |
| 74018 | <1% | 88 | $497.10 | |
| 87077 | <1% | 191 | $481.83 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,280 | $451.72 |
| 86769 | <1% | 16 | $450.27 | |
| 82746 | <1% | 51 | $442.40 | |
| 97116 | <1% | 16 | $441.61 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,988 | $431.78 |
| 82248 | <1% | 98 | $397.14 | |
| 73610 | <1% | 125 | $346.46 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 758 | $339.87 |
| 84550 | <1% | 116 | $309.43 | |
| 73562 | <1% | 39 | $274.59 | |
| 84703 | <1% | 1,105 | $270.16 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 356 | $256.13 |
| 87807 | <1% | 609 | $226.98 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,286 | $217.84 |
| 83550 | <1% | 42 | $196.20 | |
| 73030 | <1% | 56 | $192.08 | |
| 85007 | <1% | 428 | $186.79 | |
| 85651 | <1% | 129 | $184.65 | |
| 80143 | <1% | 239 | $180.80 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,064 | $178.94 |
| 92557 | <1% | 55 | $175.00 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,504 | $139.66 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 441 | $139.53 |
| 86141 | <1% | 24 | $126.46 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,212 | $125.24 |
| 86780 | <1% | 49 | $124.37 | |
| 76870 | <1% | 13 | $109.08 | |
| 80179 | <1% | 144 | $92.75 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 44 | $84.44 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 153 | $79.57 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 835 | $79.16 |
| 85046 | <1% | 52 | $77.14 | |
| J3490 | Unclassified drugs | <1% | 459 | $73.23 |
| 92567 | <1% | 55 | $70.00 | |
| 99406 | <1% | 12 | $68.85 | |
| 82570 | <1% | 24 | $65.54 | |
| 83615 | <1% | 14 | $61.18 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 432 | $56.60 |
| 86592 | <1% | 59 | $54.98 | |
| 81015 | <1% | 1,026 | $42.85 | |
| 84100 | <1% | 27 | $29.07 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 348 | $26.86 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 304 | $20.33 |
| 73130 | <1% | 14 | $15.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 13 | $11.43 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 195 | $7.65 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 993 | $5.50 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 646 | $5.30 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 197 | $4.24 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 871 | $3.18 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 48 | $1.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 70 | $0.56 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 13 | $0.00 |
| A4550 | Surgical trays | 0% | 61 | $0.00 |
| 10E0XZZ | 0% | 36 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 202 | $0.00 |
| 84145 | 0% | 27 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 57 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 37 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 21 | $0.00 |
| 99080 | 0% | 227 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 13 | $0.00 |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 0% | 26 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 66 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDIFIGLIA, MARIO (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Bon Secours Community Hospital | Port Jervis, NY | $10.48M |
| ST. Anthony Community Hospital | Warwick, NY | $4.31M |
| Good Samaritan Hospital of Suffern | West Nyack, NY | $81K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.